Treatment of multiple myeloma in the elderly: realities and hopes.

Abstract:

:Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and safety of MP versus MP-based therapies including new agents such as thalidomide (MPT) or bortezomib (MPV). In all these studies response rate and progression-free survival were superior in patients receiving MPT or MPV. However, these new combinations are not without side effects, and the incidence of grade 3 and 4 toxicities is higher than that reported with MP. Besides, the median duration of the complete remissions obtained with these new combinations is still insufficient, ranging from 15 to 27 months, and new therapeutic alternatives are still needed in this subset of patients. The purpose of this review article is to summarize the currently available data in the front-line treatment of elderly patients with MM and to discuss which questions are still unsolved in the management of this subset of patients.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

De La Rubia J,Sanz MA

doi

10.3109/10428194.2010.530361

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

9-14

issue

1

eissn

1042-8194

issn

1029-2403

journal_volume

52

pub_type

杂志文章,评审
  • Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures.

    abstract::EBER in situ hybridization (EBER) and LMP-1 immunohistochemistry (LMP-1) are widely used for identifying Epstein-Barr virus (EBV) within tumor cells of Hodgkin lymphoma (HL), but measurement error has never been formally evaluated. To determine assay reliability, 40 HL tumors with known EBV status were stained for bot...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819032000141310

    authors: Glaser SL,Gulley ML,Borowitz MJ,Craig FE,Mann RB,Stewart SL,Shema SJ,Ambinder RF

    更新日期:2004-03-01 00:00:00

  • Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy.

    abstract::Secondary malignancies represent a relevant complication of chemotherapy employed for a previous cancer. Acute leukemias represent the most frequent secondary malignancy in the first decade following primary neoplasms; secondary leukemias are generally myeloid and can be preceeded by a myelodysplastic syndrome. The bi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009113377

    authors: Pagano L,Pulsoni A,Mele L,Leone G

    更新日期:2000-11-01 00:00:00

  • Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

    abstract::We retrospectively examined the results of a new chemo-free approach combining blinatumomab with ponatinib (blina/pona) in 26 relapsed/refractory Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patients. All but one achieved complete morphologic remission, and 23 achieved a complete molecular response. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1844198

    authors: Couturier MA,Thomas X,Raffoux E,Huguet F,Berthon C,Simand C,Gallego-Hernanz MP,Hicheri Y,Hunault Berger M,Saillard C,Leguay T,Loiseau C,Béné MC,Chevallier P

    更新日期:2020-11-06 00:00:00

  • Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery.

    abstract::Factors associated with failure of antifungal therapy were examined in 42 cancer patients with fusariosis (1987-1997). Thirty-six patients (86%) had leukemia and 39 (93%) were neutropenic. Disseminated infection was the most common presentation. The majority (83%) received amphotericin B-based therapy. Thirty patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000149386

    authors: Kontoyiannis DP,Bodey GP,Hanna H,Hachem R,Boktour M,Girgaway E,Mardani M,Raad II

    更新日期:2004-01-01 00:00:00

  • Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

    abstract::Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indir...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802005191

    authors: Vallet S,Palumbo A,Raje N,Boccadoro M,Anderson KC

    更新日期:2008-07-01 00:00:00

  • Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

    abstract::Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400003267

    authors: Arora B,Mesa R,Tefferi A

    更新日期:2004-12-01 00:00:00

  • Lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 expression on B-cell subsets and the effects of splenectomy-experimental studies.

    abstract::There is an abundance of data dealing with recirculation of T cells in the rats, but relatively little is known about the traffic of B cells. The adhesion molecules expressed on the surface membrane are of great significance for recirculation of lymphocytes. However, very little is known about the expression of variou...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000033006

    authors: Milićević NM,Milićević Z,Westermann J

    更新日期:2002-11-01 00:00:00

  • Predicting long-term survival in multiple myeloma patients following autotransplants.

    abstract::Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000067567

    authors: Fassas AB,Van Rhee F,Tricot G

    更新日期:2003-05-01 00:00:00

  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.

    abstract::Follicular lymphoma (FL) is characterized by an initial response to treatment with inevitable relapse. We evaluated chemoimmunotherapy resistance (CIR resistance) including transformation. We identified patients who received rituximab combination therapy for symptomatic FL. CIR resistance was defined as disease progre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.885513

    authors: Mozessohn L,Cheung MC,Crump M,Buckstein R,Berinstein N,Imrie K,Kuruvilla J,Piliotis E,Kukreti V

    更新日期:2014-11-01 00:00:00

  • Techniques for detection of minimal residual disease.

    abstract::Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509075308

    authors: Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

    更新日期:1995-01-01 00:00:00

  • Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder.

    abstract::Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors. We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract. One is a granulocytic sarcoma of the extrahepatic bile duct, another is an extramedullary plasmacytoma of the gallbladder, and the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.483300

    authors: Hwang DW,Lim CS,Jang JY,Lee SE,Yoon SO,Jeon YK,Uk Lee K,Kim SW

    更新日期:2010-07-01 00:00:00

  • Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

    abstract::The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400014991

    authors: Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

    更新日期:2005-02-01 00:00:00

  • Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and lymphoplasmacytic lymphoma.

    abstract::An unusual case of aplastic anemia presenting in association with lymphoplasmacytic lymphoma and paroxysmal nocturnal hemoglobinuria is discussed. An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological cl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500085057

    authors: Veidt RG,Ansari-Lari A,Brodsky RA

    更新日期:2005-08-01 00:00:00

  • BCR-ABL directed immunotherapy: a virtual reality?

    abstract::Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009060331

    authors: Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

    更新日期:2000-06-01 00:00:00

  • Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.

    abstract::We have studied the functional properties of topoisomerase II (Topo II) in a subclone of the HL-60 cell line, which is highly resistant to cytotoxic Topo II inhibitors, but does not express p-glycoprotein. The cells contain the two forms of human topo II with Mr 170 and 180 kDa in equal proportions. Two different stat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148538

    authors: Boege F,Gieseler F,Biersack H,Meyer P

    更新日期:1993-03-01 00:00:00

  • Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.

    abstract::In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.578310

    authors: Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

    更新日期:2011-09-01 00:00:00

  • Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.

    abstract::This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145740

    authors: Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

    更新日期:1999-10-01 00:00:00

  • The role of radiation therapy in the management of primary central nervous system lymphoma.

    abstract::Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone revealed a robust initial response but high rates of local recurrence with long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based chemotherapy ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2014.961014

    authors: Milgrom SA,Yahalom J

    更新日期:2015-05-01 00:00:00

  • Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.

    abstract::Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1330474

    authors: Wendtner CM,Gregor M

    更新日期:2018-02-01 00:00:00

  • Expression of c-kit receptor (CD117) and CD34 in leukemic cells.

    abstract::The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509049769

    authors: Muroi K,Nakamura M,Amemiya Y,Suda T,Miura Y

    更新日期:1995-01-01 00:00:00

  • Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

    abstract::The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.496017

    authors: Brown JR

    更新日期:2010-08-01 00:00:00

  • Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors.

    abstract::To define the initial characteristics and prognostic factors of patients with conjunctival low-grade malignant lymphoma, all patients treated for low-grade lymphoma with initial conjunctival involvement were reviewed. Forty-nine cases were selected, including 45 cases with exclusive ophthalmologic conjunctival involve...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500518966

    authors: Meunier J,Lumbroso-Le Rouïc L,Dendale R,Vincent-Salomon A,Asselain B,Arnaud P,Némati F,Fourquet A,Desjardins L,Plancher C,Levy C,Chaoui D,Validire P,Decaudin D

    更新日期:2006-07-01 00:00:00

  • Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.

    abstract::Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) have been implicated in the pathogenesis of adult T-cell leukemia/lymphoma, but their effects on T-cells have not been well studied. Here we analyzed the functions of PTHrP and MIP-1α on T-cell growth and death both in vitro an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.626883

    authors: Shu ST,Dirksen WP,Lanigan LG,Martin CK,Thudi NK,Werbeck JL,Fernandez SA,Hildreth BE 3rd,Rosol TJ

    更新日期:2012-04-01 00:00:00

  • Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.

    abstract::Gain-of-function EZH2 mutation promotes H3K27 trimethylation (H3K27me3) and lymphoid transformation of germinal center (GC) derived B-cell lymphoma, such as GCB diffuse large B-cell lymphoma (DLBCL), but not activated B-cell (ABC) DLBCL. It is unclear whether expression levels of EZH2 and consequential H3K27me3 vary b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1006220

    authors: Zhou Z,Gao J,Popovic R,Wolniak K,Parimi V,Winter JN,Licht JD,Chen YH

    更新日期:2015-01-01 00:00:00

  • Significance of circulating plasma cells in multiple myeloma.

    abstract::The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049709

    authors: Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

    更新日期:1994-08-01 00:00:00

  • Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOAG17V and IDH2R172 hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma.

    abstract::We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10+ lymphoma cells ranged widely f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1768382

    authors: Hayashida M,Maekawa F,Chagi Y,Iioka F,Kobashi Y,Watanabe M,Ohno H

    更新日期:2020-10-01 00:00:00

  • Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.

    abstract::In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one pat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600580817

    authors: Rodriguez V,Anderson PM,Litzow MR,Erlandson L,Trotz BA,Arndt CA,Khan SP,Wiseman GA

    更新日期:2006-08-01 00:00:00

  • Acute large bowel pseudo-obstruction due to multiple myeloma.

    abstract::Involvement of the gastrointestinal (GI) tract by multiple myeloma (MM) is extremely rare. The small intestine and stomach are the most frequent sites of spread. We report 1 case of a 61-year-old woman who presented with clinical and radiographic features of an acute large bowel pseudo-obstruction. An abdominal comput...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001697322

    authors: Venizelos I,Theodoridou S,Vakalopoulou S,Perifanis V,Vyzantiadis T,Garipidou V

    更新日期:2004-09-01 00:00:00

  • Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

    abstract::A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000151923

    authors: Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

    更新日期:2004-03-01 00:00:00